22q.11.2 Deletion Syndrome

Bezafibrate Restores Blood–Brain Barrier Function in 22q11.2 Models, Study Finds

The peer-reviewed preclinical study flags a path to repurpose an FDA-approved cholesterol drug class, with patient trials still required.